Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates

8-K filing — Inhibrx Biosciences, Inc. (INBX)

Filed: 2026-09-08 AccNo: 0002007919-26-000047 Size: 5 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Inhibrx Biosciences shares are trading lower. The company announced primary endpoint results from the Phase 2 HexAgon study of INBRX-106, an OX40 agonist, combined with pembrolizumab versus pembrolizumab alone in PD-L1 positive head and neck squamous cell carcinoma.

Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times

'FDA’s Acting Drug, Vaccine Regulators Tapped for Permanent Roles'- Bloomberg

1 No-Brainer ETF I'm Loading Up on in 2026 and Beyond

The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as a core holding for long-term investors seeking diversified dividend income. With a 3% dividend yield (three times higher than S&P 500 ETFs), low 0.06% expense ratio, and exposure to stable sectors like healthcare and consumer staples, SCHD offers attractive passive income potential. The ETF has delivered 29% total returns year-to-date and is particularly suitable for tax-advantaged accounts like Roth IRAs.

Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?

The article compares two healthcare-focused ETFs from iShares: IHE (Pharmaceuticals ETF) with 55 holdings and IYH (Healthcare ETF) with 100 holdings. While IHE delivered stronger 1-year returns of 50% versus IYH's 27.4%, the article recommends IYH as the better choice due to superior 3- and 5-year performance, greater diversification, and larger asset base of $3.9B. Both funds have identical 0.37% expense ratios.